Updated 2025-2026 formulations of mRNA-1283 and BNT162b2 protect older adults against severe COVID-19 outcomes and medically attended illness.

On May 20, 2025, the Food and Drug Administration announced a new stance on who should receive the COVID-19 vaccine. The agency said it would approve new versions of the vaccine only for adults 65 ...

COVID-19 vaccination is still recommended for most older adults, including two doses a year for everyone over age 65 and anyone with a compromised immune system, and one dose a year for those under 65 ...

While a CDC report on Wednesday confirms that seniors are most at risk at developing a serious illness from the coronavirus, the virus also poses a risk to younger adults, according to the guidance.

This post was written by Laura Shannonhouse, Mary Chase Mize, Matthew Fullen, Jamie Aten, and Michael Porter. Previously, we talked about the perils of social isolation and loneliness, and how a lack ...

As the nation gears up for the rollout of an updated COVID-19 vaccine, a new study shows the economic benefits of continued broad vaccination in adults. In fact, the country would ultimately save more ...

There are significant economic benefits of COVID-19 vaccination, particularly for older adults, with a single dose being cost-effective across all age groups. A second dose is economically favorable ...

The first influenza vaccine built on messenger RNA technology heads to US shelves this fall.

Adults 65 years and older are disproportionately impacted by COVID-19 and at higher risk for severe disease and hospitalizations. “Today’s recommendation allows older adults to receive an additional ...

The FDA approved Moderna’s mFlusiva, America’s first mRNA flu vaccine, for adults 50 and older. Here’s how its approval and effectiveness differ by age.

In a landmark decision for vaccine science, the US Food and Drug Administration (FDA) has approved the world's first ...

Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced U.S. availability of ...